차세대 시퀀싱 라이브러리 준비 시장 규모, 점유율, 동향 분석 보고서 : 시퀀싱 유형별, 제품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Next-generation Sequencing Library Preparation Market Summary

The global next-generation sequencing library preparation market size was estimated at USD 2.0 billion in 2025 and is projected to reach USD 5.3 billion by 2033, growing at a CAGR of 13.5% from 2026 to 2033. Rapid advancements in sequencing technology and bioinformatics have enabled the identification of DNA variations.

Moreover, with the widespread application of NGS and Whole-Genome Sequencing (WGS), a wide range of genes can be examined in a single platform simultaneously, which expands the utility of DNA sequencing in clinical diagnosis applications. These factors are expected to drive substantial growth in the market over the forecast period.

The rapid advancement of genomic research is a major driver fueling the demand for next-generation sequencing (NGS) library preparation kits. As scientists delve deeper into understanding the genetic basis of diseases, biological processes, and evolutionary mechanisms, NGS has become an indispensable tool. Applications such as whole genome sequencing, targeted sequencing, and transcriptomics require diverse and specialized library preparation methods to convert DNA or RNA samples into sequencing-ready formats. This broadening scope of research, particularly in cancer genomics, where identifying tumor mutations and heterogeneity is critical, and in rare genetic disorders, where pinpointing causative mutations is essential, continuously increases the need for efficient, accurate, and high-quality library prep solutions.

Global Next-generation Sequencing Library Preparation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global next-generation sequencing library preparation market report based on sequencing type, product, application, end use, and region:

• Sequencing Type Outlook (Revenue, USD Million, 2021 - 2033)
• Targeted Genome Sequencing
• Whole Genome Sequencing
• Whole Exome Sequencing
• Other Sequencing Types
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Reagents & Consumables
  • DNA Library Preparation Kits
  • RNA Library Preparation Kits
  • Other Reagents & Consumables
• Instruments
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug & Biomarker Discovery
• Disease Diagnostics
  • Cancer Diagnostics
  • Reproductive Health Diagnostics
  • Infectious Disease Diagnostics
  • Other Disease Diagnostic Applications
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals and Clinics
• Academic and Research Institutions
• Pharmaceutical and Biotechnology Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Sequencing Type Segment
  • 1.2.2. Product Segment
  • 1.2.3. Application Segment
  • 1.2.4. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segmental Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, and Scope

• 3.1. Market Lineage
  • 3.1.1. Parent Market Analysis
  • 3.1.2. Ancillary Market Analysis
• 3.2. Next-generation Sequencing Library Preparation Market - Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Case Study Insight
• 3.4. Market Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
  • 3.4.2. SWOT Analysis, By Factor (Political & Legal, Economic And Technological)

Chapter 4. Next-generation Sequencing Library Preparation Market: Sequencing Type Business Analysis

• 4.1. Sequencing Type Segment Dashboard
• 4.2. Global Next-generation Sequencing Library Preparation Market Sequencing Type Movement Analysis, 2025 & 2033
• 4.3. Global Next-generation Sequencing Library Preparation Market Size & Trend Analysis, by Sequencing Type, 2021 to 2033 (USD Million)
• 4.4. Targeted Genome Sequencing
  • 4.4.1. Global Targeted Genome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.5. Whole Genome Sequencing
  • 4.5.1. Global Whole Genome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.6. Whole Exome Sequencing
  • 4.6.1. Global Whole Exome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.7. Other Sequencing Types
  • 4.7.1. Global Other Sequencing Types Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Next-generation Sequencing Library Preparation Market: Product Business Analysis

• 5.1. Product Segment Dashboard
• 5.2. Global Next-generation Sequencing Library Preparation Market Product Movement Analysis, 2025 & 2033
• 5.3. Global Next-generation Sequencing Library Preparation Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 5.4. Reagents & Consumables
  • 5.4.1. Global Reagents & Consumables Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. DNA Library Preparation Kits
    • 5.4.2.1. Global DNA Library Preparation Kits Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. RNA Library Preparation Kits
    • 5.4.3.1. Global RNA Library Preparation Kits Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Other Reagents & Consumables
    • 5.4.4.1. Global Other Reagents & Consumables Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 5.5. Instruments
  • 5.5.1. Global Instruments Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Next-generation Sequencing Library Preparation Market: Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global Next-generation Sequencing Library Preparation Market Application Movement Analysis, 2025 & 2033
• 6.3. Global Next-generation Sequencing Library Preparation Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Drug & Biomarker Discovery
  • 6.4.1. Global Drug & Biomarker Discovery Next-generation Sequencing Library Preparation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Disease Diagnostics
  • 6.5.1. Global Disease Diagnostics Next-generation Sequencing Library Preparation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Cancer Diagnostics
    • 6.5.2.1. Global Cancer Diagnostics Next-generation Sequencing Library Preparation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Reproductive Health Diagnostics
    • 6.5.3.1. Global Reproductive Health Diagnostics Next-generation Sequencing Library Preparation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. Infectious Disease Diagnostics
    • 6.5.4.1. Global Infectious Disease Diagnostics Next-generation Sequencing Library Preparation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Other Disease Diagnostic Applications
    • 6.5.5.1. Global Other Disease Diagnostic Applications Next-generation Sequencing Library Preparation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Global Others Next-generation Sequencing Library Preparation Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Next-generation Sequencing Library Preparation Market: End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global Next-generation Sequencing Library Preparation Market End Use Movement Analysis, 2025 & 2033
• 7.3. Global Next-generation Sequencing Library Preparation Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Hospitals and Clinics
  • 7.4.1. Global Hospitals and Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Academic and Research Institutions
  • 7.5.1. Global Academic and Research Institutions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Pharmaceutical and Biotechnology Companies
  • 7.6.1. Global Pharmaceutical and Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Next-generation Sequencing Library Preparation Market: Regional Estimates & Trend Analysis by Sequencing Type, Product, Application, and End Use

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Regulatory framework
    • 8.4.2.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Target disease prevalence
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Regulatory framework
    • 8.4.3.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Target disease prevalence
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Regulatory framework
    • 8.4.4.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Target disease prevalence
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Regulatory framework
    • 8.5.2.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Target disease prevalence
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Regulatory framework
    • 8.5.3.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Target disease prevalence
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Regulatory framework
    • 8.5.4.5. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Target disease prevalence
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Regulatory framework
    • 8.5.5.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Target disease prevalence
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Regulatory framework
    • 8.5.6.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Target disease prevalence
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Regulatory framework
    • 8.5.7.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Target disease prevalence
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Regulatory framework
    • 8.5.8.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key country dynamics
    • 8.5.9.2. Target disease prevalence
    • 8.5.9.3. Competitive scenario
    • 8.5.9.4. Regulatory framework
    • 8.5.9.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Target disease prevalence
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Regulatory framework
    • 8.6.2.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Target disease prevalence
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Regulatory framework
    • 8.6.3.5. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Target disease prevalence
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Regulatory framework
    • 8.6.4.5. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Target disease prevalence
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Regulatory framework
    • 8.6.5.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Target disease prevalence
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Regulatory framework
    • 8.6.6.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Target disease prevalence
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Regulatory framework
    • 8.6.7.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Target disease prevalence
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Regulatory framework
    • 8.7.2.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Target disease prevalence
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. Regulatory framework
    • 8.7.3.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Target disease prevalence
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Regulatory framework
    • 8.8.2.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Target disease prevalence
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Regulatory framework
    • 8.8.3.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Target disease prevalence
    • 8.8.4.3. Competitive scenario
    • 8.8.4.4. Regulatory framework
    • 8.8.4.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key country dynamics
    • 8.8.5.2. Target disease prevalence
    • 8.8.5.3. Competitive scenario
    • 8.8.5.4. Regulatory framework
    • 8.8.5.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2025
• 9.4. Company Profiles/Listing
  • 9.4.1. Illumina, Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Agilent Technologies, Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. F. Hoffmann-La Roche AG, Inc.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. BD
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Oxford Nanopore Technologies
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. New England Biolabs Inc.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Revvity, Inc.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. QIAGEN N.V.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Pacific Biosciences of California, Inc.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Thermo Fisher Scientific Inc.
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives